LEADER 04829nam 22009253u 450 001 996339091503316 005 20231129014806.0 010 $a1-280-30974-1 010 $a9786610309740 010 $a1-84692-556-8 035 $a(CKB)1000000000463450 035 $a(EBL)362703 035 $a(OCoLC)476194143 035 $a(SSID)ssj0000258330 035 $a(PQKBManifestationID)12112418 035 $a(PQKBTitleCode)TC0000258330 035 $a(PQKBWorkID)10257141 035 $a(PQKB)10109792 035 $a(EXLCZ)991000000000463450 100 $a20130418d2005|||| u|| | 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aTherapeutic Strategies in Lymphoid Malignancies$b[electronic resource] $eAn Immunotherapeutic Approach 210 $aOxford $cAtlas Medical Publishing Ltd$d2005 215 $a1 online resource (238 p.) 225 1 $aTherapeutic Strategies 300 $aDescription based upon print version of record. 311 $a1-904392-52-0 327 $aContents; Contributors; 1. The history of immunotherapy for lymphoid malignancies; 2. Immunological markers of lymphoid malignancy; 3. Diagnostic and prognostic markers of lymphoid malignancies; the latest genetic, cytogenetic and haematological parameters; 4. CD20: B-cell antigen and therapeutic target; 5. Rituximab and chemotherapy for non-Hodgkin's lymphomas: improved response and survival; 6. Rituximab and chemotherapy in elderly patients with lymphomas; 7. Maintenance therapy with rituximab; 8. Interferon-alpha in lymphoid malignancies 327 $a9. Radioimmunotherapy safety: radiation protection, administration guidelines, isotope comparison, and quality of life issues10. Radioimmunotherapy with Yttrium-90-labelled ibritumomab tiuxetan (ZevalinTM) for B-cell Hodgkin's lymphoma; 11. Radioimmunotherapy combinations with other therapies for non-Hodgkin's lymphoma; 12. 131I-Tositumomab therapy for the treatment ofl ow-grade non-Hodgkin's lymphoma; 13. CD52 as a target for immunotherapy; 14. Relapsed and refractory CLL: a clinical challenge 327 $a15. Optimising the use of alemtuzumab in CLL: new therapeutic end points, disease stratification and therapy earlier in the disease course16. Alemtuzumab in combination with other therapies in B-cell lymphoproliferative disorders; 17. The role of alemtuzumab in allogeneic stem cell transplantation; 18. Alemtuzumab in T-cell malignancies; 19. Epratuzumab: A new humanised monoclonal antibody to CD22; 20. Education and management of patients undergoing immunotherapy and radioimmunotherapy; 21. Antibody therapy for chronic lymphocytic leukemia; Index 330 $aTargeted therapies are the focus of much research in oncology. Encouraging results from the development of new monoclonal antibodies are revolutionizing clinical therapies and this is particularly the case for haematologic malignancies. The advent of immunotherapy heralds a new era particularly for patients who are refractory to more traditional therapies. Impressive results are evident using monoclonal antibodies (mAb) that a) bind with high specificity to cell-surface antigens, resulting in targeted killing of the malignant cells or b) are conjugated to radioisotopes, toxins, enzymes or drug 410 0$aTherapeutic Strategies 606 $aCancer 606 $aLymphatics 606 $aLymphoma 606 $aLymphoma 606 $aImmunotherapy 606 $aLymphoproliferative Disorders 606 $aNeoplasms by Histologic Type 606 $aImmunomodulation 606 $aLymphatic Diseases 606 $aBiological Therapy 606 $aImmunoproliferative Disorders 606 $aNeoplasms 606 $aImmune System Diseases 606 $aDiseases 606 $aTherapeutics 606 $aHemic and Lymphatic Diseases 606 $aDiagnostic Techniques and Procedures 615 4$aCancer. 615 4$aLymphatics. 615 4$aLymphoma. 615 2$aLymphoma 615 2$aImmunotherapy 615 2$aLymphoproliferative Disorders 615 2$aNeoplasms by Histologic Type 615 2$aImmunomodulation 615 2$aLymphatic Diseases 615 2$aBiological Therapy 615 2$aImmunoproliferative Disorders 615 2$aNeoplasms 615 2$aImmune System Diseases 615 2$aDiseases 615 2$aTherapeutics 615 2$aHemic and Lymphatic Diseases 615 2$aDiagnostic Techniques and Procedures 676 $a616.994420637 700 $aHillmen$b P$01001216 701 $aWitzig$b TE$01001217 801 0$bAU-PeEL 801 1$bAU-PeEL 801 2$bAU-PeEL 906 $aBOOK 912 $a996339091503316 996 $aTherapeutic Strategies in Lymphoid Malignancies$92298040 997 $aUNISA